ClinicalTrials.Veeva

Menu

Cardiac RadiothErapy for VEntricular Tachycardia II (CREVET II)

U

Universitaire Ziekenhuizen KU Leuven

Status

Enrolling

Conditions

Ventricular Tachycardia (VT)

Treatments

Procedure: stereotactic radiotherapy ablation

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Steoreotactic therapy radioablation has become a standard of care option for patients with therapy-refractory ventricular tachycardia, yet long-term outcome is lacking. The objective of this study is to evaluate the long-term outcomes, both efficacy and safety, after STAR in patients with therapy-refractory ventricular tachycardia.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Eligible for STAR for therapy-refractory VT based on a multidisciplinary discussion
  • Ability to give a written informed consent and willingness to return for follow-up

Exclusion criteria

  • Contra-indications for STAR, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy < 6 months in the absence of VT
  • Any condition that is deemed a contraindication in the judgment of the investigators

Trial contacts and locations

1

Loading...

Central trial contact

Bert Vandenberk, MD PhD; Patrick Berkovic, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems